On October 30, 2025, REGENXBIO Inc. announced the completion of enrollment in the AFFINITY DUCHENNE® pivotal trial of RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy, as well as the successful production of the first batches intended for commercial supply.
The company also released a supplemental Community Letter that can be viewed by clicking here.
Please click here to view all details in their press release.